Industry News
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Companies with more exposure to the UK, the EU, South Korea and Japan are likely on better footing as these countries have secured favorable agreements capping tariffs at around 15%.
Discover What's Happening
Business Sustainability Updates, Straight to Your Inbox
Explore our newsletters
Join our Newsletter to receive the latest industry trends, expert tips, and exclusive insights delivered straight to your inbox!
.png)
